BACKGROUND: Flavin-containing monooxygenases (FMO) catalyze the metabolism of nucleophilic heteroatom-containing drugs and xenobiotics, including nicotine. Rare mutations in FMO3 are responsible for defective N-oxidation of dietary trimethylamine leading to trimethylaminuria, and common genetic variation in FMO3 has been linked to interindividual variability in metabolic function that may be substrate specific. METHODS: A genetic model of CYP2A6 function is used as a covariate to reveal functional polymorphism in FMO3 that indirectly influences the ratio of deuterated nicotine metabolized to cotinine following oral administration. The association is tested between FMO3 haplotype and cigarette consumption in a set of nicotine-dependent smokers. RESULTS: FMO3 haplotype, based on all common coding variants in Europeans, significantly predicts nicotine metabolism and accounts for ∼2% of variance in the apparent percent of nicotine metabolized to cotinine. The metabolic ratio is not associated with FMO2 haplotype or an FMO1 expression quantitative trait locus. Cross-validation demonstrates calculated FMO3 haplotype parameters to be robust and significantly improve the predictive nicotine metabolism model over CYP2A6 genotype alone. Functional classes of FMO3 haplotypes, as determined by their influence on nicotine metabolism to cotinine, are also significantly associated with cigarettes per day in nicotine-dependent European Americans (n=1025, P=0.04), and significantly interact (P=0.016) with CYP2A6 genotype to predict cigarettes per day. CONCLUSION: These findings suggest that common polymorphisms in FMO3 influence nicotine clearance and that these genetic variants in turn influence cigarette consumption.
BACKGROUND: Flavin-containing monooxygenases (FMO) catalyze the metabolism of nucleophilic heteroatom-containing drugs and xenobiotics, including nicotine. Rare mutations in FMO3 are responsible for defective N-oxidation of dietary trimethylamine leading to trimethylaminuria, and common genetic variation in FMO3 has been linked to interindividual variability in metabolic function that may be substrate specific. METHODS: A genetic model of CYP2A6 function is used as a covariate to reveal functional polymorphism in FMO3 that indirectly influences the ratio of deuterated nicotine metabolized to cotinine following oral administration. The association is tested between FMO3 haplotype and cigarette consumption in a set of nicotine-dependent smokers. RESULTS:FMO3 haplotype, based on all common coding variants in Europeans, significantly predicts nicotine metabolism and accounts for ∼2% of variance in the apparent percent of nicotine metabolized to cotinine. The metabolic ratio is not associated with FMO2 haplotype or an FMO1 expression quantitative trait locus. Cross-validation demonstrates calculated FMO3 haplotype parameters to be robust and significantly improve the predictive nicotine metabolism model over CYP2A6 genotype alone. Functional classes of FMO3 haplotypes, as determined by their influence on nicotine metabolism to cotinine, are also significantly associated with cigarettes per day in nicotine-dependent European Americans (n=1025, P=0.04), and significantly interact (P=0.016) with CYP2A6 genotype to predict cigarettes per day. CONCLUSION: These findings suggest that common polymorphisms in FMO3 influence nicotine clearance and that these genetic variants in turn influence cigarette consumption.
Authors: Laura Jean Bierut; Pamela A F Madden; Naomi Breslau; Eric O Johnson; Dorothy Hatsukami; Ovide F Pomerleau; Gary E Swan; Joni Rutter; Sarah Bertelsen; Louis Fox; Douglas Fugman; Alison M Goate; Anthony L Hinrichs; Karel Konvicka; Nicholas G Martin; Grant W Montgomery; Nancy L Saccone; Scott F Saccone; Jen C Wang; Gary A Chase; John P Rice; Dennis G Ballinger Journal: Hum Mol Genet Date: 2006-12-07 Impact factor: 6.150
Authors: Chang-Shin Park; Ju-Hee Kang; Woon-Gye Chung; Hyun-Gyu Yi; Jae-Eun Pie; Dong-Kyun Park; R N Hines; D G McCarver; Young-Nam Cha Journal: Pharmacogenetics Date: 2002-01
Authors: Sharon E Murphy; Peter Villalta; Sing-Wei Ho; Linda B von Weymarn Journal: J Chromatogr B Analyt Technol Biomed Life Sci Date: 2007-06-29 Impact factor: 3.205
Authors: Sharon K Krueger; David E Williams; Mei-Fei Yueh; Sarah R Martin; Ronald N Hines; Judy L Raucy; Colin T Dolphin; Elizabeth A Shephard; Ian R Phillips Journal: Drug Metab Rev Date: 2002-08 Impact factor: 4.518
Authors: Meghan J Chenoweth; Andy Z X Zhu; Lisa Sanderson Cox; Jasjit S Ahluwalia; Neal L Benowitz; Rachel F Tyndale Journal: Pharmacogenet Genomics Date: 2014-03 Impact factor: 2.089
Authors: Sharon E Murphy; Sung-Shim L Park; Elizabeth F Thompson; Lynne R Wilkens; Yesha Patel; Daniel O Stram; Loic Le Marchand Journal: Carcinogenesis Date: 2014-09-18 Impact factor: 4.944
Authors: A Joseph Bloom; Linda B von Weymarn; Maribel Martinez; Laura J Bierut; Alison Goate; Sharon E Murphy Journal: Pharmacogenet Genomics Date: 2013-12 Impact factor: 2.089
Authors: James W Baurley; Christopher S McMahan; Carolyn M Ervin; Bens Pardamean; Andrew W Bergen Journal: Trends Mol Med Date: 2018-02-04 Impact factor: 11.951
Authors: Meijuan Xu; Deepak Kumar Bhatt; Catherine K Yeung; Katrina G Claw; Amarjit S Chaudhry; Andrea Gaedigk; Robin E Pearce; Ulrich Broeckel; Roger Gaedigk; Deborah A Nickerson; Erin Schuetz; Allan E Rettie; J Steven Leeder; Kenneth E Thummel; Bhagwat Prasad Journal: J Pharmacol Exp Ther Date: 2017-08-17 Impact factor: 4.030
Authors: Andrew W Bergen; Martha Michel; Denise Nishita; Ruth Krasnow; Harold S Javitz; Karen N Conneely; Christina N Lessov-Schlaggar; Hyman Hops; Andy Z X Zhu; James W Baurley; Jennifer B McClure; Sharon M Hall; Timothy B Baker; David V Conti; Neal L Benowitz; Caryn Lerman; Rachel F Tyndale; Gary E Swan Journal: PLoS One Date: 2015-07-01 Impact factor: 3.240
Authors: Yadira X Perez-Paramo; Gang Chen; Joseph H Ashmore; Christy J W Watson; Shamema Nasrin; Jennifer Adams-Haduch; Renwei Wang; Yu-Tang Gao; Woon-Puay Koh; Jian-Min Yuan; Philip Lazarus Journal: Cancer Epidemiol Biomarkers Prev Date: 2018-10-31 Impact factor: 4.254